These terms and conditions govern your use of the website alphaminr.com and its related services.
These Terms and Conditions (“Terms”) are a binding contract between you and Alphaminr, (“Alphaminr”, “we”, “us” and “service”). You must agree to and accept the Terms. These Terms include the provisions in this document as well as those in the Privacy Policy. These terms may be modified at any time.
Your subscription will be on a month to month basis and automatically renew every month. You may terminate your subscription at any time through your account.
We will provide you with advance notice of any change in fees.
You represent that you are of legal age to form a binding contract. You are responsible for any
activity associated with your account. The account can be logged in at only one computer at a
time.
The Services are intended for your own individual use. You shall only use the Services in a
manner that complies with all laws. You may not use any automated software, spider or system to
scrape data from Alphaminr.
Alphaminr is not a financial advisor and does not provide financial advice of any kind. The service is provided “As is”. The materials and information accessible through the Service are solely for informational purposes. While we strive to provide good information and data, we make no guarantee or warranty as to its accuracy.
TO THE EXTENT PERMITTED BY APPLICABLE LAW, UNDER NO CIRCUMSTANCES SHALL ALPHAMINR BE LIABLE TO YOU FOR DAMAGES OF ANY KIND, INCLUDING DAMAGES FOR INVESTMENT LOSSES, LOSS OF DATA, OR ACCURACY OF DATA, OR FOR ANY AMOUNT, IN THE AGGREGATE, IN EXCESS OF THE GREATER OF (1) FIFTY DOLLARS OR (2) THE AMOUNTS PAID BY YOU TO ALPHAMINR IN THE SIX MONTH PERIOD PRECEDING THIS APPLICABLE CLAIM. SOME STATES DO NOT ALLOW THE EXCLUSION OR LIMITATION OF INCIDENTAL OR CONSEQUENTIAL OR CERTAIN OTHER DAMAGES, SO THE ABOVE LIMITATION AND EXCLUSIONS MAY NOT APPLY TO YOU.
If any provision of these Terms is found to be invalid under any applicable law, such provision shall not affect the validity or enforceability of the remaining provisions herein.
This privacy policy describes how we (“Alphaminr”) collect, use, share and protect your personal information when we provide our service (“Service”). This Privacy Policy explains how information is collected about you either directly or indirectly. By using our service, you acknowledge the terms of this Privacy Notice. If you do not agree to the terms of this Privacy Policy, please do not use our Service. You should contact us if you have questions about it. We may modify this Privacy Policy periodically.
When you register for our Service, we collect information from you such as your name, email address and credit card information.
Like many other websites we use “cookies”, which are small text files that are stored on your computer or other device that record your preferences and actions, including how you use the website. You can set your browser or device to refuse all cookies or to alert you when a cookie is being sent. If you delete your cookies, if you opt-out from cookies, some Services may not function properly. We collect information when you use our Service. This includes which pages you visit.
We use Google Analytics and we use Stripe for payment processing. We will not share the information we collect with third parties for promotional purposes. We may share personal information with law enforcement as required or permitted by law.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Delaware
|
52-0849320
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
Class
|
Outstanding as of
May 6
, 2015
|
|
|
Common Stock, $0.0001 par value
|
28,611,967
shares
|
|
Page No.
|
||
|
1
|
||
|
1
|
||
|
2
|
||
|
3
|
||
|
4
|
||
|
15
|
||
|
18
|
||
|
18
|
||
|
19
|
||
|
22
|
||
|
24
|
||
|
25
|
||
|
March 31,
|
December 31,
|
|||||||
|
2015
|
2014
|
|||||||
| (Unaudited) | ||||||||
|
ASSETS
|
||||||||
|
Current assets
|
||||||||
|
Cash and cash equivalents
|
$ | 111 | $ | 805 | ||||
|
Marketable securities
|
2,861 | 3,500 | ||||||
|
Prepaid expenses and other assets
|
71 | 107 | ||||||
|
Total current assets
|
3,043 | 4,412 | ||||||
|
Property and equipment, net
|
4 | 4 | ||||||
|
Patent portfolios
|
52,582 | 55,004 | ||||||
|
Goodwill
|
1,712 | 1,712 | ||||||
|
Deposit
|
26 | 26 | ||||||
|
Total assets
|
$ | 57,367 | $ | 61,158 | ||||
|
LIABILITIES AND STOCKHOLDERS' EQUITY
|
||||||||
|
Current liabilities
|
||||||||
|
Accounts payable and accrued expenses
|
$ | 674 | $ | 728 | ||||
|
Accrued salaries and benefits
|
634 | 329 | ||||||
|
Short-term lease liabilities
|
174 | 173 | ||||||
|
Total current liabilities
|
1,482 | 1,230 | ||||||
|
Long-term lease liabilities
|
363 | 407 | ||||||
|
Total liabilities
|
1,845 | 1,637 | ||||||
|
Series I redeemable preferred stock, $0.0001 par value; 35,541 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively; liquidation preference of $167 per share
|
5,935 | 5,935 | ||||||
|
Commitments and contingencies
|
||||||||
|
Stockholders' equity
|
||||||||
|
Preferred Stock, $0.0001 par value, 50,000,000 shares authorized;
|
||||||||
|
Series A: no shares issued and outstanding at March 31, 2015 and December 31, 2014; liquidation preference $0.0001 per share
|
||||||||
|
Convertible preferred stock
|
- | - | ||||||
|
Series C: 1 share issued and outstanding at March 31, 2015 and December 31, 2014; liquidation preference $0.0001 per share
|
- | - | ||||||
|
Series D: 4,725 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively; liquidation value of $0.0001 per share
|
- | - | ||||||
|
Series D-1: 834 shares issued and outstanding, at March 31, 2015 and December 31, 2014, respectively; liquidation value of $0.0001 per share
|
- | - | ||||||
|
Series F-1: no shares issued and outstanding, at March 31, 2015 and December 31, 2014, respectively; liquidation preference $0.0001 per share
|
- | - | ||||||
|
Series H: 439,043 shares issued and outstanding at March 31, 2015 and December 31, 2014, respectively; liquidation preference $83.50 per share
|
- | - | ||||||
|
Series J: no shares issued and outstanding at March 31, 2015 and December 31, 2014; liquidation preference $0.0001 per share
|
- | - | ||||||
|
Common stock, $0.0001 par value, 200,000,000 shares authorized; 28,612,195 and 28,609,695 shares issued at March 31, 2015 and December 31, 2014, respectively; 28,611,967 and 28,609,467 shares outstanding at March 31, 2015 and December 31, 2014, respectively
|
3 | 3 | ||||||
|
Additional paid-in-capital
|
137,742 | 137,655 | ||||||
|
Treasury stock, at cost, 228 shares at March 31, 2015 and December 31, 2014, respectively
|
(264 | ) | (264 | ) | ||||
|
Accumulated deficit
|
(87,894 | ) | (83,808 | ) | ||||
|
Total stockholders' equity
|
49,587 | 53,586 | ||||||
|
Total liabilities and stockholders' equity
|
$ | 57,367 | $ | 61,158 | ||||
|
Three Months Ended March 31,
|
||||||||
|
2015
|
2014
|
|||||||
|
Revenues
|
$ | 2 | $ | 4 | ||||
|
Operating costs and expenses
|
||||||||
|
Amortization of patent portfolio
|
2,422 | 2,428 | ||||||
|
Compensation and related expenses (including stock-based compensation)
|
719 | 3,532 | ||||||
|
Professional fees
|
729 | 1,150 | ||||||
|
Rent
|
22 | 67 | ||||||
|
Other selling, general and administrative
|
226 | 836 | ||||||
|
Total operating expenses
|
4,118 | 8,013 | ||||||
|
Loss from operations
|
(4,116 | ) | (8,009 | ) | ||||
|
Other income
|
||||||||
|
Other income, net
|
30 | 46 | ||||||
|
Total other income
|
30 | 46 | ||||||
|
Net loss
|
$ | (4,086 | ) | $ | (7,963 | ) | ||
|
Net loss per share, basic and diluted
|
$ | (0.14 | ) | $ | (1.66 | ) | ||
|
Weighted average number of common shares outstanding,
|
||||||||
|
Basic and diluted
|
28,611,855 | 4,789,596 | ||||||
|
Three Months Ended March 31,
|
||||||||
|
2015
|
2014
|
|||||||
|
Cash flows from operating activities
|
||||||||
|
Net loss
|
$ | (4,086 | ) | $ | (7,963 | ) | ||
|
Adjustments to reconcile net loss to net cash used in operating activities:
|
||||||||
|
Amortization of patent portfolio
|
2,422 | 2,428 | ||||||
|
Non-cash registration rights penalty
|
- | 700 | ||||||
|
Fair value adjustment for warrant liabilities
|
- | (40 | ) | |||||
|
Stock-based compensation
|
87 | 3,396 | ||||||
|
Unrealized gain on marketable securities
|
57 | - | ||||||
|
Changes in assets and liabilities:
|
||||||||
|
Marketable securities
|
582 | - | ||||||
|
Prepaid expenses and other assets
|
36 | 44 | ||||||
|
Accounts payable and accrued expenses
|
(54 | ) | 69 | |||||
|
Accrued salaries and benefits
|
305 | (156 | ) | |||||
|
Accrued lease liabilities
|
(43 | ) | - | |||||
|
Net cash used in operating activities
|
(694 | ) | (1,522 | ) | ||||
|
Cash flows from investing activities
|
||||||||
|
Payment of accrued patent costs
|
- | (1,000 | ) | |||||
|
Net cash used in investing activities
|
- | (1,000 | ) | |||||
|
Cash flows from financing activities
|
||||||||
|
Proceeds from issuance of common stock and warrants, net
|
- | 3,900 | ||||||
|
Net cash provided by financing activities
|
- | 3,900 | ||||||
|
Net (decrease) increase in cash and cash equivalents
|
(694 | ) | 1,378 | |||||
|
Cash and cash equivalents, beginning of period
|
805 | 3,125 | ||||||
|
Cash and cash equivalents, end of period
|
$ | 111 | $ | 4,503 | ||||
|
Cash paid for interest and taxes
|
$ | - | $ | - | ||||
|
Non-cash investing and financing activities
|
||||||||
|
Retirement of treasury stock
|
- | 201 | ||||||
|
Conversion of preferred stock to common stock
|
- | 1 | ||||||
|
Note 1.
|
Organization and Descript
io
n of Business
|
|
Note 2.
|
Liquidity and Financial Condition
|
|
●
|
managing current cash and cash equivalents on hand from the Company’s past equity offerings,
|
|
●
|
seeking additional funds raised through the sale of additional securities in the future,
|
|
●
|
seeking additional liquidity through credit facilities or other debt arrangements, and
|
|
●
|
increasing revenue from its patent portfolios, license fees and new business ventures.
|
|
Note 3.
|
Summary of Significant Accounting Policies
|
|
As of March 31,
|
||||||||
|
2015
|
2014
|
|||||||
|
Convertible preferred stock
|
5,156,841
|
16,773,275
|
||||||
|
Warrants to purchase common stock
|
769,803
|
775,021
|
||||||
|
Non-vested restricted stock awards
|
-
|
10,000
|
||||||
|
Options to purchase common stock
|
5,298,877
|
3,323,876
|
||||||
|
Total
|
11,225,521
|
20,882,172
|
||||||
|
Note 4.
|
Goodwill and Intangible Assets
|
|
Date Acquired and Description
|
Patent Portfolios at December 31, 2014, Net
|
Original Life
(in years)
|
Amortization Expense for the Three Months Ended March 31, 2015
|
Patent Portfolios at March 31, 2015, Net
|
||||||||||||
|
7/24/13 - Rockstar patent portfolio
|
$
|
3,322
|
8.50
|
$
|
116
|
$
|
3,206
|
|||||||||
|
9/10/13 - North South patent portfolio
|
932
|
8.50
|
32
|
900
|
||||||||||||
|
12/31/13 - Rockstar patent portfolio
|
50,750
|
6.50
|
2,274
|
48,476
|
||||||||||||
|
$
|
55,004
|
$
|
2,422
|
$
|
52,582
|
|||||||||||
|
Rockstar
Portfolio
|
North South
Portfolio
|
Rockstar
Portfolio
|
Total
Amortization
|
|||||||||||||
|
Nine Months Ended December 31, 2015
|
354
|
98
|
6,951
|
7,403
|
||||||||||||
|
Year Ended December 31, 2016
|
471
|
130
|
9,250
|
9,851
|
||||||||||||
|
Year Ended December 31, 2017
|
470
|
130
|
9,225
|
9,825
|
||||||||||||
|
Year Ended December 31, 2018
|
470
|
130
|
9,225
|
9,825
|
||||||||||||
|
Year Ended December 31, 2019
|
470
|
130
|
9,225
|
9,825
|
||||||||||||
|
Thereafter
|
971
|
282
|
4,600
|
5,853
|
||||||||||||
|
Total
|
$
|
3,206
|
$
|
900
|
$
|
48,476
|
$
|
52,582
|
||||||||
|
Note 5.
|
Fair Value of Financial Assets and Liabilities
|
|
Fair value measured at March 31, 2015
|
||||||||||||||||
|
Total carrying
value at
March 31,
|
Quoted prices in active markets
|
Significant other observable inputs
|
Significant unobservable inputs
|
|||||||||||||
|
2015
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
|||||||||||||
|
Assets
|
||||||||||||||||
|
Marketable securities - mutual funds
|
$
|
2,861
|
$
|
2,861
|
$
|
-
|
$
|
-
|
||||||||
|
Fair value measured at December 31, 2014
|
||||||||||||||||
|
Total carrying
value at
December 31,
|
Quoted prices in active markets
|
Significant other observable inputs
|
Significant unobservable inputs
|
|||||||||||||
|
2014
|
(Level 1)
|
(Level 2)
|
(Level 3)
|
|||||||||||||
|
Assets
|
||||||||||||||||
|
Marketable securities - mutual funds
|
$
|
3,500
|
$
|
3,500
|
$
|
-
|
$
|
-
|
||||||||
|
Note 6.
|
Stockholders’ Equity
|
|
Number of Shares Issued and Outstanding as of
|
|||||||||||||
|
March 31,
2015
|
December 31,
2014
|
Par Value
|
Conversion Ratio
|
||||||||||
|
Series "A"
|
-
|
-
|
$
|
0.0001
|
N/A
|
||||||||
|
Series "C"
|
1
|
1
|
0.0001
|
1:1
|
|||||||||
|
Series “D"
|
4,725
|
4,725
|
0.0001
|
10:1
|
|||||||||
|
Series “D-1"
|
834
|
834
|
0.0001
|
10:1
|
|||||||||
|
Series “F-1"
|
-
|
-
|
0.0001
|
1:1
|
|||||||||
|
Series “H"
|
439,043
|
439,043
|
0.0001
|
10:1
|
|||||||||
|
Series “I”
|
35,541
|
35,541
|
0.0001
|
20:1
|
|||||||||
|
Series “J”
|
-
|
-
|
0.0001
|
1:1
|
|||||||||
|
Warrants
|
Weighted Average Exercise Price
|
Total Intrinsic Value
|
Weighted Average Remaining Contractual Life (in years)
|
|||||||||||||
|
Outstanding as of December 31, 2014
|
769,803
|
$
|
13.70
|
$
|
-
|
4.03
|
||||||||||
|
Issued
|
-
|
-
|
- | - | ||||||||||||
|
Cancelled
|
-
|
-
|
- | - | ||||||||||||
|
Outstanding as of March 31, 2015
|
769,803
|
$
|
13.70
|
$
|
-
|
3.79
|
||||||||||
|
Number of Shares
|
Weighted Average Exercise Price
|
Total Intrinsic Value
|
Weighted Average Remaining Contractual Life (in years)
|
|||||||||||||
|
Outstanding as of December 31, 2014
|
5,243,877
|
$
|
4.97
|
$
|
-
|
6.0
|
||||||||||
|
Employee options granted
|
-
|
-
|
- | - | ||||||||||||
|
Outstanding as of March 31, 2015
|
5,243,877
|
$
|
4.97
|
$
|
-
|
5.8
|
||||||||||
|
Options vested and expected to vest
|
5,243,877
|
$
|
4.97
|
$
|
-
|
5.8
|
||||||||||
|
Options vested and exercisable
|
4,943,752
|
$
|
5.09
|
$
|
-
|
5.8
|
||||||||||
|
Number of Shares
|
Weighted Average Exercise Price
|
Total Intrinsic Value
|
Weighted Average Remaining Contractual Life (in years)
|
||||||||||
|
Outstanding as of December 31, 2014
|
55,000
|
$
|
5.16
|
$
|
-
|
6.4
|
|||||||
|
Non-employee options granted
|
-
|
-
|
- |
-
|
|||||||||
|
Outstanding as of March 31, 2015
|
55,000
|
$
|
5.16
|
$
|
-
|
6.2
|
|||||||
|
Options vested and expected to vest
|
55,000
|
$
|
5.16
|
$
|
-
|
6.2
|
|||||||
|
Options vested and exercisable
|
55,000
|
$
|
5.16
|
$
|
-
|
6.2
|
|||||||
|
Number of Units
|
Weighted Average Grant Day Fair Value
|
|||||||
|
Nonvested at December 31, 2014
|
7,500
|
$
|
2.63
|
|||||
|
Vested
|
(5,000
|
)
|
3.01
|
|||||
|
Nonvested at March 31, 2015
|
2,500
|
$
|
1.35
|
|||||
|
For the Three Months Ended March 31,
|
||||||||
|
2015
|
2014
|
|||||||
|
Employee restricted stock awards
|
$
|
11
|
$
|
2
|
||||
|
Employee stock option awards
|
76
|
3,394
|
||||||
|
Total compensation expense
|
$
|
87
|
$
|
3,396
|
||||
|
Note 7.
|
Related Party Transactions
|
|
Note 8.
|
Commitments and Contingencies
|
|
Note 9.
|
Subsequent Events
|
|
●
|
managing current cash and cash equivalents on hand from our past equity offerings,
|
|
●
|
seeking additional funds raised through the sale of additional securities in the future,
|
|
●
|
seeking additional liquidity through credit facilities or other debt arrangements, and
|
|
●
|
increasing revenue from the monetization of its patent portfolios, license fees, and new business ventures.
|
|
31.1
|
Certification of Chief Executive Officer of Spherix Incorporated pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
31.2
|
Certification of Chief Financial Officer of Spherix Incorporated pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
|
|
32.1
|
Certification of Chief Executive Officer of Spherix Incorporated pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
32.2
|
Certification of Chief Financial Officer of Spherix Incorporated pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
|
|
101.INS
|
XBRL Instance Document.
|
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
|
Spherix Incorporated
(Registrant)
|
||
|
Date: May
8
, 2015
|
By:
/s/ Anthony Hayes
Anthony Hayes
Chief Executive Officer
(Principal Executive Officer)
|
|
|
Date: May
8
, 2015
|
By:
/s/ Richard Cohen
Richard Cohen
Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)
|
|
No information found
* THE VALUE IS THE MARKET VALUE AS OF THE LAST DAY OF THE QUARTER FOR WHICH THE 13F WAS FILED.
| FUND | NUMBER OF SHARES | VALUE ($) | PUT OR CALL |
|---|
| DIRECTORS | AGE | BIO | OTHER DIRECTOR MEMBERSHIPS |
|---|
No information found
No Customers Found
No Suppliers Found
Price
Yield
| Owner | Position | Direct Shares | Indirect Shares |
|---|